View Exam | PowerPak

1. A key role of pharmacists in caring for patients with AD being prescribed TCSs is to address “corticophobia.” It is crucial for pharmacists to:

A. Counsel patients on the low risk of adverse effects as well as the importance of medication adherence to effectively manage the disease B. Recommend patients continue emollient therapy during TCS treatment C. Have the patient and caregiver review an article on the percentage of fears of TCS treatment D. A and B E. Unsure

2. Which of the following scoring systems can be used to assess atopic dermatitis disease severity via the assessment of both visual lesions AND subjective symptoms?

A. SCORing of Atopic Dermatitis (SCORAD) index B. Patient-Oriented Eczema Measure (POEM) C. Eczema Area and Severity Index (EASI) D. A, B, and C are all correct E. Unsure

3. Which of the following agents has been historically associated with the development of malignancies?

A. Topical corticosteroids B. Topical calcineurin inhibitors C. Emollients D. Crisaborole ointment E. Unsure

4. Which of the following topical therapies is first-line in the prevention of atopic dermatitis flares?

A. Topical corticosteroids B. Topical calcineurin inhibitors C. Emollients D. Crisaborole ointment E. Unsure

5. Ariel is a 3-year old girl with a history of atopic dermatitis. She presents with her mom to your pharmacy with an acute flare. She currently uses an emollient and is not using any other medications. Which is the following is an appropriate recommendation for an acute flare of atopic dermatitis?

A. Topical calcineurin inhibitors B. Systemic calcineurin inhibitors C. Topical corticosteroids D. Systemic steroids E. Unsure

6. Jasmine is a 28-year-old that has been battling atopic dermatitis since childhood. Recently, her physician prescribed her topical calcineurin inhibitors to apply to newly affected areas on her face. She picked her up prescription 3 days ago and presents back to the pharmacy complaining of burning and tingling on her face. She says she's been compliant with the topical calcineurin inhibitor and asks you for advice. What do you recommend?

A. Recommend she contact her doctor to switch agents B. Assure her that it is a known reaction and will go away with continued use C. Inform her that it's a sign of worsening eczema and she needs to visit her physician for additional therapies D. Inform her that calcineurin inhibitors are not recommended for her face and that she discontinue use E. Unsure

7. Which of the following is true about the use of topical corticosteroids in atopic dermatitis?

A. There is no role of topical corticosteroids to prevent flares of AD B. There is strong data to support tapering of topical corticosteroids after resolution of a flare C. Topical corticosteroids can be tapered after the resolution of itch during a flare D. Topical corticosteroids can be used as first line therapy in all affected areas of AD E. Unsure

8. Systemic options for atopic dermatitis include all of the following EXCEPT:

A. Azathioprine B. Tacrolimus C. Methotrexate D. Cyclosporine E. Unsure

9. Which of the following available agents has the most robust data, including an FDA label for the treatment of moderate-to severe atopic dermatitis?

A. Dupilumab B. Mycophenolate mofetil C. Tofacitinib D. Cyclosporine E. Unsure

10. Which key mediator in atopic dermatitis does dupilumab target?

A. Immunoglobulin (Ig)-E B. Interleukin (IL)-4-receptor-α C. Dihydrofolate reductase D. Calcineurin phosphatase E. Unsure

Evaluation Questions

11. How confident are you in your treatment recommendation for Ariel?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

12. How confident are you in your decision about treating adverse effects for your patient Jasmine in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A key role of pharmacists in caring for patients with AD being prescribed TCSs is to address “corticophobia.” It is crucial for pharmacists to:

2. Which of the following scoring systems can be used to assess atopic dermatitis disease severity via the assessment of both visual lesions AND subjective symptoms?

3. Which of the following agents has been historically associated with the development of malignancies?

4. Which of the following topical therapies is first-line in the prevention of atopic dermatitis flares?

5. Ariel is a 3-year old girl with a history of atopic dermatitis. She presents with her mom to your pharmacy with an acute flare. She currently uses an emollient and is not using any other medications. Which is the following is an appropriate recommendation for an acute flare of atopic dermatitis?

7. Which of the following is true about the use of topical corticosteroids in atopic dermatitis?

8. Systemic options for atopic dermatitis include all of the following EXCEPT:

9. Which of the following available agents has the most robust data, including an FDA label for the treatment of moderate-to severe atopic dermatitis?

10. Which key mediator in atopic dermatitis does dupilumab target?

Evaluation Questions

11. How confident are you in your treatment recommendation for Ariel?

12. How confident are you in your decision about treating adverse effects for your patient Jasmine in the question above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A key role of pharmacists in caring for patients with AD being prescribed TCSs is to address “corticophobia.” It is crucial for pharmacists to:

2. Which of the following scoring systems can be used to assess atopic dermatitis disease severity via the assessment of both visual lesions AND subjective symptoms?

3. Which of the following agents has been historically associated with the development of malignancies?

4. Which of the following topical therapies is first-line in the prevention of atopic dermatitis flares?

5. Ariel is a 3-year old girl with a history of atopic dermatitis. She presents with her mom to your pharmacy with an acute flare. She currently uses an emollient and is not using any other medications. Which is the following is an appropriate recommendation for an acute flare of atopic dermatitis?

7. Which of the following is true about the use of topical corticosteroids in atopic dermatitis?

8. Systemic options for atopic dermatitis include all of the following EXCEPT:

9. Which of the following available agents has the most robust data, including an FDA label for the treatment of moderate-to severe atopic dermatitis?

10. Which key mediator in atopic dermatitis does dupilumab target?

Evaluation Questions

11. How confident are you in your treatment recommendation for Ariel?

12. How confident are you in your decision about treating adverse effects for your patient Jasmine in the question above?

« Return to Activity

Customers who Purchased
this Activity also Purchased